Cancer Discovery

New Paper Highlights Role of Immune Stimulating Cells that Shrink Advanced Breast Cancer Tumors

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, published a paper that shed light to the novel mechanism of action of BriaCell’s lead product candidate, Bria-IMT™ in the journal of Frontiers in Immunology, the 5th most cited journal in Immunology. The novel mechanism of action of Bria-IMT™, also referred […]

Pharmaceutical Business News

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III […]

cancer Cancer Discovery

Researchers quantify breast cancer risk based on rare variants and background risk

Rare variants combined with background genetic risk factors may account for many unexplained cases of familial breast cancer, and knowing the specific genes involved could inform choice of prevention and treatment strategies, according to findings presented in a plenary session at the American Society of Human Genetics (ASHG) 2017 Annual Meeting in Orlando, Fla. Researchers […]

Arthritis Vaccines

$1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine

Rheumatoid Arthritis is a chronic inflammatory disease that mainly targets the synovial membrane, cartilage and bone.  It affects about 1% of the global population and is associated with significant morbidity and increased mortality. Anti-TNF related therapies are the current standard treatment of patients with advanced RA, but over half of the RA patients do not […]

Cardiology

Late Stage Critical Limb Ischemia Study using Placental Cell Therapy Snags $8 Million Grant from Europe’s Horizon 2020 Program

The European Union awarded an $8 million grant to cell therapy developer, Pluristem Therapeutics Inc., earmarked for a late stage trial in critical limb ischemia (CLI) program. The grant is part of the European Union’s Horizon 2020 program, which is its largest Research and Innovation program. The Phase III study of PLX-PAD in CLI will […]